SIRT2 negatively regulates insulin resistance in C2C12 skeletal muscle cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1372-1378

  Arora, Amita ^a   Dey, Chinmoy Sankar ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

Insulin resistance; Insulin signaling; SIRT2; Sirtuins; Skeletal muscle

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; SIRTUIN 2; SIRTUIN 3; SMALL INTERFERING RNA; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVE SITE; GENE OVEREXPRESSION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; ENZYME PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

INSULIN RESISTANCE; INSULIN SIGNALING; SIRT2; SIRTUINS; SKELETAL MUSCLE;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; GLUCOSE; HYPOGLYCEMIC AGENTS; IMMUNOPRECIPITATION; INSULIN; INSULIN RESISTANCE; MICE; MUSCLE, SKELETAL; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIRTUIN 2;

EID: 84903463140     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.027     Document Type: Article

References (30)

1. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6:307-319.
2. Yoshizaki T., Milne J.C., Imamura T., Schenk S., Sonoda N., Babendure J.L., Lu J.C., Smith J.J., Jirousek M.R., Olefsky J.M. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 2009, 29:1363-1374.
3. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
4. Kitada M., Kume S., Kanasaki K., Takeda-Watanabe A., Koya D. Sirtuins as possible drug targets in type 2 diabetes. Curr. Drug Targets 2013, 14:622-636.
5. Jing E., Emanuelli B., Hirschey M.D., Boucher J., Lee K.Y., Lombard D., Verdin E.M., Kahn C.R. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14608-14613.
6. Xiao C., Kim H.S., Lahusen T., Wang R.H., Xu X., Gavrilova O., Jou W., Gius D., Deng C.X. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem. 2010, 285:36776-36784.
7. Jing E., Gesta S., Kahn C.R. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007, 6:105-114.
8. Pandithage R., Lilischkis R., Harting K., Wolf A., Jedamzik B., Luscher-Firzlaff J., Vervoorts J., Lasonder E., Kremmer E., Knoll B., Luscher B. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J. Cell Biol. 2008, 180:915-929.
9. Wang F., Nguyen M., Qin F.X., Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007, 6:505-514.
10. Jiang W., Wang S., Xiao M., Lin Y., Zhou L., Lei Q., Xiong Y., Guan K.L., Zhao S. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 2011, 43:33-44.
11. Luthi-Carter R., Taylor D.M., Pallos J., Lambert E., Amore A., Parker A., Moffitt H., Smith D.L., Runne H., Gokce O., Kuhn A., Xiang Z., Maxwell M.M., Reeves S.A., Bates G.P., Neri C., Thompson L.M., Marsh J.L., Kazantsev A.G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7927-7932.
12. Kumar N., Dey C.S. Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochem. Pharmacol. 2003, 65:249-257.
13. Kumar N., Dey C.S. Metformin enhances insulin signaling in insulin-dependent and -independent pathways in insulin resistant muscle cells. Br. J. Pharmacol. 2002, 137:329-336.
14. Kumar N., Dey C.S. Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J. Exp. Biol. 2002, 205:3739-3746.
15. Verma N.K., Singh J., Dey C.S. PPAR-γ expression modulates insulin sensitivity in C2C12 skeletal muscle cells. Br. J. Pharmacol. 2004, 143:1006-1013.
16. Bisht B., Goel H.L., Dey C.S. Focal adhesion kinase regulates insulin resistance in skeletal muscle. Diabetologia 2007, 50:1058-1069.
17. Gupta A., Dey C.S. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol. Cell. Endocrinol. 2009, 309:55-62.
18. Blodgett A.B., Kothinti R.K., Kamyshko I., Petering D.H., Kumar S., Tabatabai N.M. A fluorescence method for measurement of glucose transport in kidney cells. Diabetes Technol. Ther. 2011, 13:743-751.
19. Cole P.A. Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 2008, 4:590-597.
20. + cosubstrate specificity of a Sir2 enzyme. Mol. Cell 2005, 17:855-868.
21. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
22. Choi Y.H., Kim H., Lee S.H., Jin Y.H., Lee K.Y. ERK1/2 regulates SIRT2 deacetylase activity. Biochem. Biophys. Res. Commun. 2013, 437:245-249.
23. Hwang S.L., Jeong Y.T., Li X., Kim Y.D., Lu Y., Chang Y.C., Lee I.K., Chang H.W. Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle. Br. J. Pharmacol. 2013, 169:69-81.
24. Chiu T.T., Sun Y., Koshkina A., Klip A. Rac-1 superactivation triggers insulin-independent glucose transporter 4 (GLUT4) translocation that bypasses signaling defects exerted by c-Jun N-terminal kinase (JNK)- and ceramide-induced insulin resistance. J. Biol. Chem. 2013, 288:17520-17531.
25. Chen J., Chan A.W., To K.F., Chen W., Zhang Z., Ren J., Song C., Cheung Y.S., Lai P.B., Cheng S.H., Ng M.H., Huang A., Ko B.C. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology 2013, 57:2287-2298.
26. Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci. Signal. 2011, 4:ra46.
27. Ramakrishnan G., Davaakhuu G., Kaplun L., Chung W.C., Rana A., Atfi A., Miele L., Tzivion G. Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin. J. Biol. Chem. January 20, 2014, 10.1074/jbc.M113.537266.
28. Wang R.H., Kim H.S., Xiao C., Xu X., Gavrilova O., Deng C.X. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J. Clin. Invest. 2011, 121:4477-4490.
29. Lu M., Sarruf D.A., Li P., Osborn O., Sanchez-Alavez M., Talukdar S., Chen A., Bandyopadhyay G., Xu J., Morinaga H., Dines K., Watkins S., Kaiyala K., Schwartz M.W., Olefsky J.M. Neuronal Sirt1 deficiency increases insulin sensitivity in both brain and peripheral tissues. J. Biol. Chem. 2013, 288:10722-10735.
30. + system. Genes Dev. 2012, 26:259-270.